Drugs / Doxapram
Doxapram
also known as
AHR-619 · Docatone · Dopram · Doxapram hcl · Doxapram Hydrochloride · Doxapram hydrochloride hydrate · Doxapram hydrochloride monohydrate · NSC-170958 · +2 more
Small molecule targets KCNK3, KCNK9 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DOPRAM | — | 1965-06-23 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06585163 | Sep → Dec 2024 overdue | — | Quivive Pharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04430790 | Jun 2020 → May 2026 overdue | apnea of prematurity, respiratory failure | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07637149 | Jun → Dec 2026 expected | — | Kasr El Aini Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02820025 | Oct 2015 → Apr 2017 | — | General Hospital of Ningxia Medical University | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT01022151 Comparator | Nov 2007 → Jul 2010 | — | King Faisal University | Completed | No outcome recorded |
| Phase 2 | NCT00477451 Background | May 2007 → Apr 2008 | — | Alexza Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 4 | NCT02171910 Comparator | Oct → Dec 2016 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00389909 Comparator | Nov 2006 → Nov 2010 | apnea of prematurity, pulmonary immaturity | Jean Michel Hascoet | Completed | No outcome recorded |
| — | NCT03894189 Comparator | May → Dec 2019 | — | Beni-Suef University | Unknown | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxapram | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01022151 ↗ |
| Known as | AHR-619 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | Docatone | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | Dopram | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | Doxapram hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | Doxapram Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585163 ↗ |
| Known as | Doxapram hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | Doxapram hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | NSC-170958 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | NSC-760347 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Known as | Stimulexin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1754 ↗ |
| Action | Inhibit | “Potassium channel subfamily K member 9 blocker” CHEMBL1754 ↗1“Potassium channel subfamily K member 3 blocker” CHEMBL1754 ↗ |
| Modality | Small molecule | — CHEMBL1754 ↗ |
| Route | Intravenous | “0.5 mg/kg doxapram IV” NCT00477451 ↗ |
| Target | KCNK3 | “Potassium channel subfamily K member 3 blocker” CHEMBL1754 ↗ |
| Target | KCNK9 | “Potassium channel subfamily K member 9 blocker” CHEMBL1754 ↗ |